Dental Care Clinics in Aguada, PR Accepting Medicare
4 Dental Care Clinics found. Showing 1 - 4
 Dr. Marco A. Del Valle, Oficina Dental Csp Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 51 Calle Estacion, Aguada, PR 00602 Phone: 787-868-7770 |
Western Dental P.s.c. Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 256 Calle La Paz, Aguada, PR 00602 Phone: 787-868-3190 |
Dr Ernesto Del Valle Rivera Csp Dentist Medicare: Not Enrolled in Medicare Practice Location: Ave Nativo Alers Edificio Coppelia, Suite 110, Aguada, PR 00602 Phone: 787-252-0125 Fax: 787-252-4266 |
Dr Monica Velez Dental Services Llc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: Centro Cooperativo De Aguada, Carr 115 Km 24.6 Suite 13, Aguada, PR 00602 Phone: 787-868-3434 Fax: 787-868-3434 |
News Archive
States that receive federal funds are more likely to implement obesity-prevention programs
States that received funding from two obesity prevention programs founded by the U.S. Centers for Disease Control & Prevention implemented more than twice as many obesity-prevention policy initiatives as states that did not receive funding, according to a study by researchers from RTI International.
Bioniche Pharma introduces Mefoxin in frozen premix bags
Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced today the launch of Mefoxin® (cefoxitin injection) frozen premix bags. The launch marks the company's first product offering to be supplied in a frozen premix bag presentation. Mefoxin (cefoxitin injection) is manufactured by Baxter Healthcare Corporation using Baxter's proprietary GALAXY container technology.
Duloxetine reduces stress urinary incontinence and improves quality of life for women
Data presented today at the 3rd International Consultation on Incontinence, provide evidence for the efficacy of duloxetine, an investigational agent for the treatment of women with stress urinary incontinence (SUI).
Dompé's investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis
The Dompé biopharmaceutical company announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has officially designated recombinant human Nerve Growth Factor (rhNGF) - the investigational biotech molecule developed by Dompé based on research by Nobel Laureate Rita Levi Montalcini - as an orphan drug for the treatment of neurotrophic keratitis.
› Verified 4 days ago